Stryker Corporation (NYSE:SYK) Q4 2023 Earnings Conference Call January 30, 2024 4:30 PM ET

Company Participants

Kevin Lobo – Chair and Chief Executive Officer

Jason Beach – Vice President-Investor Relations

Glenn Boehnlein – Chief Financial Officer

Conference Call Participants

Robbie Marcus – JPMorgan

Lawrence Biegelsen – Wells Fargo

Ryan Zimmerman – BTIG

Joanne Wuensch – Citi

Vijay Kumar – Evercore ISI

Shagun Singh – RBC

Pito Chickering – Deutsche Bank

Travis Steed – Bank of America

Matthew O’Brien – Piper Sandler

Josh Jennings – TD Cowen

Chris Pasquale – Nephron

Danielle Antalffy – UBS

Matt Miksic – Barclays

Caitlin Cronin – Canaccord Genuity

Steven Lichtman – Oppenheimer

Mike Matson – Needham & Company, Inc.

Drew Ranieri – Morgan Stanley

Matt Taylor – Jefferies

Richard Newitter – Truist Securities

Operator

Welcome to the Fourth Quarter and Full Year 2023 Stryker Earnings Call. My name is Luke, and I'll be your operator for today's call. At this time all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes.

Before we begin, I'd like to remind you that discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.

I'd now like to turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.

Kevin Lobo

Welcome to Stryker's fourth quarter earnings call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Jason Beach, Vice President of Investor Relations. For today's call, I'll provide opening comments, followed by Jason with the trends we saw during the quarter, MAKO performance insights and updates on recent acquisitions. Glenn will then provide additional details regarding our quarterly results and 2024 guidance before opening the call to Q&A.

First, I want to recognize and celebrate our achievement of surpassing $20 billion in sales. We continue to be a high-growth company with a focus on our mission to deliver for our patients and customers. As we begin 2024, I am very excited about our future. We are in a strong position with robust demand across both procedures and capital, easing macro constraints and a strong pipeline of innovation. I want to thank our over 50,000 employees for their unrelenting determination, agility and performance.